Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?

Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?

Item
http://www.wikidata.org/entity/Q36144296
Inflammatory genomicsRegulation of Liver Enriched Transcription Factors in Rat Hepatocytes Cultures on Collagen and EHS Sarcoma MatricesDesigning toxicogenomics studies that use DNA array technologyIn vivo-in vitro toxicogenomic comparison of TCDD-elicited gene expression in Hepa1c1c7 mouse hepatoma cells and C57BL/6 hepatic tissueToxicogenomic Screening of Replacements for Di(2-Ethylhexyl) Phthalate (DEHP) Using the Immortalized TM4 Sertoli Cell LineToxicogenomics in regulatory ecotoxicology.Optimal sampling of rat liver tissue for toxicogenomic studiesExpression biomarkers for clinical efficacy and outcome prediction in cancer.Translating genomic biomarkers into clinically useful diagnostics.Toxicogenomics in drug discovery and drug development: potential applications and future challenges.A retrospective analysis of toxicogenomics in the safety assessment of drug candidates.Oxygenomics in environmental stress.A decade of toxicogenomic research and its contribution to toxicological science.DNA microarray-based gene expression profiling of estrogenic chemicals.Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood.Estimation strategies for reacting to the identification of an association between the genome and adverse drug reactions.
P2860

Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?

Item
http://www.wikidata.org/entity/Q36144296
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
@ast
Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
@en
type
label
Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
@ast
Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
@en
prefLabel
Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
@ast
Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
@en
P2093
P304
P31
P356
10.1016/J.MRFMMM.2005.02.009
P407
P433
P478
P577
P698